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Abstract
Inhibition of angiogenesis is a promising addition to current cancer treatment strategies. Neutralization of vascular
endothelial growth factor by monoclonal antibodies is clinically effective but may cause side effects due to thrombosis. Low
molecular weight angiogenesis inhibitors are currently less effective than antibody treatment and are also associated with
serious side effects. The discovery of new chemotypes with efficient antiangiogenic activity is therefore of pertinent interest.
(S)-Levamisole hydrochloride, an anthelminthic drug approved for human use and with a known clinical profile, was recently
shown to be an inhibitor of angiogenesis in vitro and exhibited tumor growth inhibition in mice. Here we describe the
synthesis and in vitro evaluation of a series of N-alkylated analogues of levamisole with the aim of characterizing structure–
activity relationships with regard to inhibition of angiogenesis. N-Methyllevamisole and p-bromolevamisole proved more
effective than the parent compound, (S)-levamisole hydrochloride, with respect to inhibition of angiogenesis and induction
of undifferentiated cluster morphology in human umbilical vein endothelial cells grown in co-culture with normal human
dermal fibroblasts. Interestingly, the cluster morphology caused by N-methyllevamisole was different than the clusters
observed for levamisole, and a third ‘‘cord-like’’ morphology resembling that of the known drug suramin was observed for
an aniline-containing derivative. New chemotypes exhibiting antiangiogenic effects in vitro are thus described, and further
investigation of their underlying mechanism of action is warranted.
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Introduction
Angiogenesis, the expansion of the blood vascular system in
response to oxygen consumption and deficiency, is essential to the
growth of cells and tissues. Normal physiological angiogenesis
takes place during growth, wound healing, the menstrual cycle,
and pregnancy [1–4]. Aberrant angiogenesis has been shown to
play an important part of the pathological processes in cancer and
other diseases such as endometriosis and rheumatoid arthritis
[1,5–8]. Since the idea that inhibition of angiogenesis could have
therapeutic potential in relation to cancer was first suggested about
40 years ago [9,10], it has been demonstrated to be beneficial with
respect to several types of cancer and may also have therapeutic
potential in other diseases associated with increased angiogenesis
[5–8,11–14]. Moreover, blood vessel normalization through
antiangiogenic treatment has emerged as a possible complemen-
tary mechanism in cancer therapy [15,16].
Vascular endothelial growth factor (VEGF), which exists in
several variants and signals through a family of VEGF receptors, is
the most important extracellular signalling molecule in the
stimulation of blood and lymph angiogenesis [3,17–19]. Currently,
the most efficient inhibitor of angiogenesis in the clinic is
bevacizumab (AvastinH; Genentech/Roche), an antibody that
binds to and thereby neutralizes the effects of VEGF, which has
shown beneficial clinical survival effects in several types of cancer
[7,20,21]. Avastin treatment, however, is accompanied by an
increased risk of venous thromboembolism [22] and the treatment
regime is expensive. This has lead to an interest in the
development of peptide-based [23] and low molecular weight
angiogenesis inhibitors. Small molecules may be desirable in many
respects, including improved pharmacokinetics and half-life in the
human body, a decreased risk of immune response, and
significantly lower production costs. Several low molecular weight
angiogenesis inhibitors have been synthesized and investigated
both in vitro and in vivo, as well as in clinical trials, and so far three
tyrosine kinase inhibitors have gained approval by the FDA for
cancer treatment [i.e., sorafenib (NexavarH; Bayer), sunitinib
(SutentH; Pfizer), and pazopanib (VotrientH; GlaxoSmithKline]
[15].
Moreover, a number of known drugs or clinical candidates with
a wide variety of phenotypes have been found to inhibit
angiogenesis. Examples include the fumagillin analogue TNP-
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470 [24], thalidomide [25,26], nonsteroidal anti-inflammatory
drugs (NSAIDs) [27], and the antifungal compound itraconazole
[28].
Likewise the anthelminthic drug (S)-levamisole hydrochloride
(ErgamisolH; 1) [29,30], which has also been used in the treatment
of rheumatoid arthritis [31,32], as well as an immunostimulant
adjuvant in chemotherapy for several types of cancer [33–36], was
recently shown to exhibit angiogenesis inhibitory activity in vitro
and tumor growth inhibition in vivo [37,38]. The in vitro
antiangiogenic effect resembled that of Avastin in several respects,
but especially with regard to inhibition of network formation and
induction of non-differentiated clusters of cells [38]. In addition,
levamisole is an alkaline phosphatase inhibitor [39,40], and recent
structure–activity relationship studies with synthetic analogues
have addressed this capacity [41,42]. Levamisole treatment,
however, has been associated with side effects [43], and the drug
was discontinued for human use in the USA in 2000, due to more
efficient alternatives. In light of the recent discovery that
levamisole exhibited antiangiogenic efficacy and that significant
tumor growth inhibition was observed at 12 mg/kg in nude mice,
we were encouraged to perform a structure–activity relationship
study based on levamisole as the parent compound.
Herein, various derivatives of levamisole, obtained either
through chemical synthesis or commercial sources, were tested
in an in vitro angiogenesis assay [44] in order to identify novel lead
structures and gain structure–activity relationships related to this
scaffold. The cationic analogue, N-methyllevamisole, proved
particularly efficacious with respect to induction of cluster
morphology and network disruption, and thus constitute an
interesting new chemotype for further investigation.
Results and Discussion
Levamisole contains a benzene ring and a hetero-substituted
bicycle [3.3.0] octene system (Figure 1A). Although the latter is not
an aromatic system, the presence of the thiourea moiety provides
the ring system with some conjugation and thereby delocalization
of the carbon–nitrogen double bond as well as the lone pairs at the
bridgehead nitrogen and the sulphur atoms. A conformational
analysis of levamisole (molecular mechanics, MMFF96s force field)
showed that levamisole preferred an ‘‘L-shaped’’ conformation
with the two ring systems being nearly perpendicular to each other
(Figure 2A–C). Due to the relatively rigid nature of this molecule,
we argue that such a conformational search reflects the preferred
conformation rather well. Generation and subsequent inspection
of GRID calculated Molecular Interaction Fields (MIFs) [45]
clearly showed that levamisole is a hydrophobic compound with
only a single directional possibility for an intermolecular in-
teraction, i.e., by hydrogen bonding via the non-bridgehead
nitrogen lone pair (Figure 2B). The predicted pKa value of
levamisole was 7.0 (see, www.chemaxon.com), which is close to
physiological pH and therefore indicates that both the neutral and
protonated forms of levamisole are likely to be present, and should
be considered equally in a structure–activity analysis. We
envisioned that if, in fact, the protonated state of levamisole was
responsible for its antiangiogenic effect, permanently cationic
analogues obtained through N-alkylation could have potential as
novel inhibitors (Figure 1B). The synthesized analogues were
tested alongside a selection of commercially available compounds
(Figure 3).
The chemistry of levamisole has been investigated to some
extent, e.g., it has been applied as a catalyst for enantioselective
transformations [46], and N-alkylated analogues have been
prepared and undergone treatment with various nucleophiles
[47–49] or investigated as a ligand in palladium-(II) complexes
[50]. Thus, in addition to the known N-alkylated analogues 7a
(methyl) [48,50] and 11a (benzyl) [48], we decided to vary the
bulk of the alkyl group, and to investigate the effect of different
counter ions (7a–12, Figure 4). Levamisole hydrochloride (1), its
racemic mixture tetramisole (2) [(6)-levamisole], p-bromolevami-
sole (3), and the aromatic compound 4 are commercially available
and were tested to complement the array of derivatives obtained
through chemical synthesis (Figure 3). Suramin (5), a well-
documented angiogenesis inhibitor, was included in the study as
well. The preparation of the N-substituted levamisole analogues
was accomplished by straightforward alkylation reactions (Figure 4)
[48,50], and the identities and purities of the synthesized
compounds were confirmed by HPLC and NMR spectroscopy,
respectively. Yields of the synthesized compounds were in the
range of 9% (N-(n-butyl)-levamisole (9)) to 57% (N-methyllevami-
sole (7)) for the isolated compounds with purities of .95% after
purification by preparative-scale reversed-phase HPLC. The
synthetic yields were not optimized, as the main focus of this
study was the biological evaluation of these compounds.
The antiangiogenic effects of the compounds were determined
in a previously developed assay [44], designed to evaluate the
growth and differentiation of human umbilical vein endothelial
cells (HUVECs) in co-culture with normal human dermal
fibroblasts (NHDF). Thus, the effect on differentiation is revealed
by HUVEC morphology and ability to form networks while the
effect on growth is revealed by HUVEC cell number (Figure 5 and
Table 1). The most efficient inhibitors were p-bromolevamisole (3)
(Figure 5C), the aniline-containing dihydro-analogue (4)
(Figure 5D), and the two different N-methyllevamisole salts (7a,
b) (Figure 5E and F), which were all more potent than (S)-
levamisole hydrochloride. The racemic tetramisole (2) (Figure 5B)
had the same effect as the enantiomerically pure parent compound
(1) (Figure 5A). The cluster morphology known from (S)-
levamisole, was also observed for tetramisole (2) (Figure 5B and
Table 1), p-bromolevamisole (3) (Figure 5C and Table 1), and N-
methyllevamisoles (7a, b), with the latter mentioned showing
a slightly more pronounced effect (Figure 5E and F, Figure 6 A–D,
Table 1). Whereas the methyl substitution at N-7 seemed to
increase the cluster inducing effect relative to compounds 1–3, the
introduction of bulkier groups (8–12) still resulted in potent
disruption of the network formation, but furnished mixed
morphologies containing both cords and clusters (Figure 5G–M
and Table 1). Compound 4 (Figure 5D and Table 1), on the other
hand, inhibited the capillary network formation to give small cords
exclusively, which is reminiscent of the effect of suramin (5)
(Figure 5N and Table 1), another well-known angiogenesis
inhibitor [44,51].
Selected compounds were tested with two different counter ions,
i.e., N-methyllevamisole [triflate (7a) and trifluoroacetate (7b)], N-
ethyllevamisole [iodide (8a) and trifluoroacetate (8b)], and N-
benzyllevamisole [bromide (11a) and trifluoroacetate (11b)]. For
each of these ion pairs, identical inhibitory effects were observed,
strongly indicating that the levamisole analogues rather than the
counter ions were responsible for the activities (Figure 5E–H, K, L,
and Table 1). N-Methyllevamisole triflate (7a) showed an IC50 for
tissue non-specific alkaline phosphatase of 0.1 mM. Since the
trifluoroacetate (7b) showed no inhibition at 2 mM or higher,
however, we speculate that the triflate counter ion may account for
the observed discrepancy in this assay.
As mentioned vide supra levamisole is an inhibitor of alkaline
phosphatase; however, when testing for inhibition of human
placenta alkaline phosphatase and tissue non-specific alkaline
phosphatase all the derivatives had IC50 values of about 1 mM or
Antiangiogenic Levamisole Derivatives
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higher and no correlation to angiogenesis inhibition was therefore
observed (Table 2). Since the inhibitory effects in the angiogenesis
assay were observed at rather high concentrations of the inhibitors,
we also tested various unrelated tertiary amine-containing
chemotypes in order to rule out non-specific effects of the
positively charged moiety. Figure 6 shows the effect of various
concentrations of N-methyllevamisole triflate (7a) compared to
high concentrations (10 mM) of BIS-TRIS, BICINE, and N-
methylimidazole, respectively. Neither BIS-TRIS nor BICINE
showed any effects even at 10 mM (Figure 6M–N), while titration
experiments showed that N-methyllevamisole triflate (7a) exerted
its cluster-inducing effect already at 30 mM (Figure 6F), which is
closer to a physiologically relevant concentration than the 1 mM
concentration used in the initial screen. N-methylimidazole had an
effect at 10 mM (Figure 6O), but no effect at 1 mM (Figure 6P).
Other amine-containing compounds (HEPES, TRICINE and
TRIZMA) neither showed an effect in the assay (results not
shown).
As previously described [38], we show that antibodies targeting
vascular endothelial growth factor (VEGF) in a concentration of
5 mg/mL inhibit endothelial cell tube formation in the co-culture
assay due to its VEGF neutralizing effect, and as a result induce
the same cluster morphology as N-methyllevamisole triflate (7a)
(Figure 6 A–D and I). Notably, this effect is identical to what is
observed in the assay when VEGF is omitted from the growth
medium [37,38], which may indicate that N-methyllevamisole
triflate (7a) effectively interferes with VEGF signalling, albeit at
relatively high concentrations. Though, based on this preliminary
test, we cannot rule out possible interaction of these chemotypes
with other phosphatases and/or kinases. In a recent publication,
several phosphatase inhibitors were shown to exhibit angiogenesis
inhibitory activity [52].
Finally, we checked compound 7a for its ability to inhibit sirtuin
1 (SIRT1) deacetylase activity in a standard fluorogenic assay in
vitro, since suramin is a known SIRT1 inhibitor [53], and SIRT1
has been shown to be a regulator of angiogenesis [54]. As expected
suramin potently inhibited SIRT1, but compound 7a exhibited no
inhibitory effect (Table 2). Rather curiously, however, elevated
values of deacetylation compared to the control wells were
observed at 10 mM and 100 mM (data not shown). Thus, to make
sure whether or not this was an artifact in the assay, we also tested
7a for its ability to activate SIRT1 compared to resveratrol, by
following standard protocols given by the supplier. These
experiments ruled out interaction with this regulatory enzyme
(Figure 7).
Intracellular signaling is mediated through several pathways,
including phosphorylation and dephosphorylation cascades, which
are of major importance [55,56]. This also applies to VEGF
signaling, which comprises several phosphorylation events, in-
cluding receptor (auto) phosphorylation [19]. Consequently,
protein kinases are potential targets for interfering with all aspects
of cell growth including angiogenesis [57]. Since kinases and
phosphatases share many substrate features, their inhibitors may
also exhibit considerable overlap in specificity within the kinase
and the phosphatase families. Therefore, levamisole and its novel
derivatives described herein may potentially influence both kinases
and phosphatases in the VEGF signaling pathway, although data
to support this hypothesis is still required to draw conclusions
regarding the mechanism of action. Interestingly, however,
levamisole was recently included in a large investigation describing
the effects of known drugs (107 compounds) on a variety of
Figure 1. Generic structures of compounds studied. A) Levamisole and resonance forms of protonated levamisole; B) resonance forms of N-
substituted analogues of levamisole.
doi:10.1371/journal.pone.0045405.g001
Figure 2. GRID calculated Molecular Interaction Fields (MIFs) for levamisole. The depicted conformation corresponds to the global energy
minimum conformation of levamisole. A) Methyl probe, contour level –1 kcal/mol; B) amide nitrogen probe, contour level –5 kcal/mol; C) carbonyl
oxygen probe, contour level –1 kcal/mol.
doi:10.1371/journal.pone.0045405.g002
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biochemical pathways in cells by protein-fragment complementa-
tion assays (PCAs; 49 included) [58]. Among others, levamisole
showed effects on Bcl-associated death promoter (BAD), Bcl-xL,
p21, mitogen-activated protein kinase 2 (MAPK2), and LIM
domain kinase 2 (Limk2), which may serve as inspiration in the
future search for the putative target of levamisole and its novel
analogues. Furthermore, it was notable, that levamisole’s closest
neighbors in a clustering analysis based on those results were the
NSAID celecoxib (also used to treat rheumatoid arthritis) and
rosuvastatin (an inhibitor of HMG-CoA-reductase, which is
natively regulated by phosphorylation) [58].
In summary, a series of derivatives of levamisole were evaluated
for their ability to inhibit angiogenesis in vitro, which revealed
several compounds that disrupted network formation and gave rise
to different morphological phenotypes. One group, including p-
bromolevamisole and tetramisole induced cluster formation
similar to that observed for levamisole, while N-methyllevamisole
was more efficient than the parent inhibitor and gave rise to
a slightly different morphology. The effect of an aniline-containing
analogue (4) resembled that of suramin by furnishing network
inhibition with small cord morphology, albeit at considerably
higher concentrations. The third group, which comprised the
majority of the N-alkylated analogues, were all inhibitors of
network formation giving rise to mixed morphologies. It should be
emphasized that both (S)-levamisole and the two derivatives (3)
and (7a) are not considered to be potent inhibitors, although the
cluster inducing effect of 7a was demonstrated down to 30 mM.
Since these compounds represent a novel scaffold for angiogenesis
inhibitors, and since the morphology observed after treatment with
N-methyllevamisole (7a) differs from that of suramin and
levamisole, we find that this novel class of chemotypes warrant
further investigation.
Future work will focus on gaining a deeper understanding of the
effects of (S)-levamisole and (S)-N-methyllevamisole on intracellular
signaling, as well as the mechanisms responsible for differentiation
and growth of endothelial cells. Development of more potent
derivatives exhibiting a similar morphological effect is of great
interest, but because levamisole is approved for clinical use, in vivo
efficacy and toxicology profiling of the novel N-methylated
inhibitor will also be an objective.
Materials and Methods
General
All reagents and solvents from commercial suppliers were used
without further purification. Alkaline phosphatase-conjugated goat
anti-mouse IgG, BICINE, BIS-TRIS, bovine kidney alkaline
phosphatase, 5-bromo-4-chloro-3-indolyl phosphate/nitro blue
tetrazolium tablets (BCIP/NBT), p-nitrophenyl phosphate sub-
strate tablets (p-NPP), and suramin were from Sigma (St. Louis,
USA). Levamisole, N-methylimidazole and tetramisole were from
Aldrich (Milwaukee, WI, USA), (–)-p-bromolevamisole oxalate was
from Sigma-Aldrich (Schnelldorf, Germany), and 4-(2,3-dihydroi-
midazo-[2,1-b]thiazol-6-yl)aniline was from Maybridge (Trevillett,
UK). Human serum albumin (HSA) and TTN buffer (0.05 M
Tris, pH 7.5, 0.3 M NaCl, 1% v/v Tween 20) were from Statens
Serum Institut (Copenhagen, Denmark). Ethanol (96%) was from
Danisco (Aalborg, Denmark). Acetic acid, acetone, DMSO,
Figure 3. Commercially obtained compounds that were tested
in this study.
doi:10.1371/journal.pone.0045405.g003
Figure 4. Structures of the N-alkylated analogues of levamisole
synthesized and tested in this study. aStandard conditions applied
for all compounds except the N-methylated analogue 7a, which was
furnished by treatment with methyltriflate in diethylether for 2 h at
room temperature as previously described [50].
doi:10.1371/journal.pone.0045405.g004
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Na2HPO4, NaH2PO4, Tween 20, NaCl, HPLC-grade acetoni-
trile, and formic acid were from Merck (Darmstadt, Germany).
Mouse anti-human CD31 was from Monosan (Uden, Nether-
lands). Goat anti-recombinant human vascular endtothelial
growth factor (Anti-VEGF), recombinant basic fibroblast growth
factor (bFGF) and recombinant human vascular endothelial
growth factor (VEGF) were from R&D Systems (Minneapolis,
MN, USA). Human umbilical vein endothelial cells (HUVEC),
normal human dermal fibroblast (NHDF), the HUVEC media-kit
EGM-2 Bulletkit, and the fibroblast media-kit FGM-2 Bulletkit
were from Clonetics, BioWhittaker (Walkersville, MD, USA).
Polystyrene 96-microwell plates were from Thermo Fischer
Scientific (Roskilde, Denmark). Trifluoroacetic acid (TFA) was
from Rathburn (Walkerburn, Scotland, UK). Porous column
material was from Applied Biosystems (Foster City, California,
USA). PBS was made from 8 mM Na2HPO4, 2 mM NaH2PO4,
0.15 M NaCl, pH 7.3. 1H and 13C NMR spectra were recorded
on a Bruker AMX 400 instrument and are reported in d units
(ppm). The solvent peak (CDCl3 or CD3OD) was used as internal
reference. Values of coupling constants J are given in Hz and the
signal multiplicities are shown in parentheses (singlet (s), doublet
(d), triplet (t), quartet (q), heptet (h), multiplet (m)). For an example
(compound 12) of a full assignment of the signals, see Table S1.
Optical rotations were measured on a 241 polarimeter (Perkin
Elmer, Waltham, Massachusets, USA). Vacuum liquid chroma-
tography (VLC) was performed with silicagel 60 H (particle size
,45 mm). Preparative reversed phase HPLC separations were
carried out on a Phenomenex Luna 250621.2 mm, C18 column
(5 mm) using an Agilent system consisting of two preparative scale
pumps, an autosampler, and a multiple-wavelength UV detector.
A gradient elution systems consisting of eluent A (H2O–MeCN–
TFA 95:5:0.1) and eluent B (H2O–MeCN–TFA 5:95:0.1), rising
linearly from 0% to 30% of B during 25 min was used. The eluent
flow rate was maintained at 20 mL/min and injection volumes
were 900 mL. HRMS was performed by Ultra High Performance
Liquid chromatography-high resolution mass spectrometry
(UHPLC-HRMS) on a maXis G3 quadrupole time-of-flight mass
spectrometer (Bruker Daltonics, Bremen, Germany) equipped with
an electrospray (ESI) source. The MS was connected to an
Ultimate 3000 UHPLC system (Dionex, Sunnyvale, CA). Sepa-
ration of 1 mL samples were performed at 40uC on a 100 mm
62.1 mm, 2.6 mm Kinetex C18 column (Phenomenex, Torrance,
CA) using a linear water-acetonitrile gradient (both buffered with
20 mM formic acid) at a flow of 0.4 mL min21 starting from 10%
Figure 5. The effect of levamisole and its analogues recorded in the in vitro angiogenesis assay performed with HUVECs growing
on a fibroblast monolayer. The images show HUVECs visualized by immunostaining for CD31 after treatment with: A) 1 mM levamisole (1); B)
1 mM tetramisole (2); C) 1 mM p-bromolevamisole (3); D) 1 mM compound 4; E) 1 mM N-methyllevamisole triflate (7a); F) 0.7 mM N-
methyllevamisole trifluoroacetate (7b); G) 0.2 mM N-ethyllevamisole trifluoroacetate (8b); H) 0.7 mM N-ethyllevamisole iodide (8a); I) 0.6 mM N-
isopropyllevamisole trifluoracetate (9); J) 0.3 mM N-butyllevamisole trifluoroacetate (10); K) 0.4 mM N-benzyllevamisole trifluoroacetate (11b); L)
0.7 mM N-benzyllevamisole bromide (11a); M) 0.1 mM N-cyclohexylmethylenelevamisole trifluoroacetate (12); N) 1 mM suramin (5); O) medium
(control); P) 0.1 % DMSO (the control was diluted 1:1000 corresponding the concentration of DMSO present when testing 1 mM of a compound
diluted from a DMSO stock solution).
doi:10.1371/journal.pone.0045405.g005
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acetonitrile and increased to 100% over 10 minutes. MS was
performed in ESI+ with a data acquisition range of 10 scans per
sec at m/z 100–1000. The MS was calibrated using sodium
formate automatically infused prior to each analytical run,
providing a mass accuracy of less than 0.5 ppm in MS mode.
(S)-Levamisole free base (6) [50]
Levamisole hydrochloride (2.00 g, 8.31 mmol) was suspended
in Et2O (50 mL) and concentrated aqueous NaOH (10 mL, 35%)
and H2O (15 mL) were added. The mixture was extracted with
Et2O (4620 mL) and the combined Et2O extracts were dried
(Na2SO4), filtered, concentrated in vacuo, and dried under high
vacuum with an oil pump overnight. The levamisole (1.68 g, 99%)
was obtained as a colorless syrup, which was used without further
purification. 1H NMR (400 MHz, 298.2 K, CD3OD): d= 3.00
(dd, 1H, J5a, 6 = 9.2, J5a, 5b = 8.6, H-5a), 3.18 (m, 1H, AB part of
a larger spin system, 2-HA/B), 3.41 (ddd, 1H, J3a, 3b = 11.0, J3a,
2A/B = 6.6, J3a, 2A/B = 4.5, H-3a), 3.61 (ddd, 1H, J3b, 3a = 11.0,
J3b, 2A/B = 6.6, J3b, 2A/B = 4.5, H-3b), 3.69 (m, 1H, A/B part of
a larger spin system, 2-HA/B), 3.72 (dd, 1H, J5b, 6 = 8.7, J5b, 5a
= 8.6, H-5b), 5.38 (t, 1H, J6, 5b/5a = 9.0, H-6), 7.32 (m, 5H, H-Ar).
13C NMR (100 MHz, 298.2 K, CD3OD): d= 35.36 (C-3), 50.23
(C-2), 59.37 (C-5), 77.52 (C-6), 127.83, 129.68 (4C, C-29, C-39, C-
59, C-69), 128.65 (C-49), 144.15 (C-19), 177.49 (C-8).
(S)-N-Methyllevamisole (7a and 7b)
Levamisole (0.233 g, 1.14 mmol) was dissolved in Et2O (10 mL)
and stirred under nitrogen atmosphere. Methyltriflate (0.164 mL,
0.24 mmol) was added and the mixture stirred for 1 h. The
reaction mixture was evaporated to dryness, and pure N-
methyllevamisole triflate (7a) was obtained as syrup after
lyophilization (.95% purity by 1H NMR). From this crude
product, 161 mg was purified by reversed phase HPLC to give N-
methyllevamisole trifluoroacetate (7b) (81 mg, 57%). Optical
rotation (7a): [a]D –83u (c 0.01, 298.2 K, CH2Cl2), lit. [a]D –
102u (ref [50]). 1H NMR (400 MHz, 298.2 K, CD3OD) the data
were identical for 7a and 7b, and agreed with the previously
published results [50]: d= 2.90 (s, 3H, H-199), 3.75 (dd, 1H, J5a, 5b
= 10.4, J5a, 6 = 9.1, H-5a), 3.90 (m, 2H, A/B part of a larger spin
system, H-2), 4.09 (m, 2H, A/B part of a larger spin system, H-3),
4.27 (t, 1H, J5b, 5a/6 = 10.4, H-5b), 5.56 (dd, 1H, J6, 5b = 10.4, J6,
5a = 9.1, H-6), 7.49 (m, 5H, H-Ar).
13C NMR (100 MHz,
298.2 K, MeOD): d= 34.0 (C-199), 38.1 (C-3), 50.2 (C-2), 56.1 (C-
5), 74.5 (C-6), 129.0, 130.8 (4C, C-29, C-39, C-59, C-69), 131.2 (C-
49), 136.9 (C-199), 179.3 (C-8). MS (m/z): [M]+ calcd, 219.1; found,
219.3.
Figure 6. The effect of anti-VEGF and various concentrations of N-methyllevamisole (7a) and suramin (5) recorded in the in vitro
angiogenesis assay performed with HUVECs growing on a fibroblast monolayer. The images show HUVECs visualized by immunostaining
for CD31 after treatment with: A) 1 mM N-methyllevamisole triflate (7a); B) 0.5 mM N-methyllevamisole triflate (7a); C) 0.25 mM N-methyllevamisole
triflate (7a); D) 0.13 mM N-methyllevamisole triflate (7a); E) 0.06 mM N-methyllevamisole triflate (7a); F) 0.03 mM N-methyllevamisole triflate (7a); G)
0.02 mM N-methyllevamisole triflate (7a); H) 0.1 % DMSO (the control was diluted 1:1000 corresponding the concentration of DMSO present in A); I)
5 mg/mL goat anti-recombinant human VEGF; J) 12 mM suramin (5); K) 1.5 mM suramin (5); L) medium (control); M) 10 mM BIS-TRIS; N) 10 mM BICINE;
O) 10 mM N-methylimidazole; P) 1 mM N-methylimidazole.
doi:10.1371/journal.pone.0045405.g006
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General procedure I; alkylation of the free base of (S)-
levamisole (6) with alkyl halides
Levamisole (6) (about 1.2 mmol) was dissolved in THF (5 mL)
and stirred under a nitrogen atmosphere. The proper iodo- or
bromoalkyl reagent (1.2 equiv) was added, and the solution was
stirred under reflux for 24 h. Then the mixture was cooled to
room temperature and concentrated in vacuo, redissolved in H2O
(25 mL), and washed with CH2Cl2 (4625 mL). The aqueous
phase was concentrated under reduced pressure, flash frozen, and
lyophilized to give the desired N-alkyl-levamisole halide, which was
tested directly and/or purified by reversed phase HPLC to give its
corresponding trifluoroacetate salt.
(S)-N-Ethyllevamisole (8a and 8b)
Levamisole (0.252 g, 1.24 mmol) and iodoethane (0.123 mL,
1.54 mmol) were subjected to general procedure I, which
furnished the iodide (8a) after lyophilization. A sample of the
colorless syrup was taken up in MeOH (0.9 mL) and purified by
reversed phase HPLC to give the N-ethyllevamisole trifluoroace-
tate (8b) (129 mg, 30%). Optical rotation (8b): [a]D –73u (c 0.01,
298.2 K, CH2Cl2).
1H NMR (400 MHz, 298.2 K, CD3OD) the
data were identical for 8a and 8b: d= 1.12 (t, 3H, J299, 199 = 7.3,
H-299), 3.20 (dq, 1H, J199a, 199b = 14.4, J199a, 299 = 7.3, H-199a), 3.35
(dq, 1H, J199b, 199a = 14.4, J199a, 299 = 7.3, H-199a), 3.77 (dd, 1H,
J5a, 5b = 10.4, J5a, 6 = 8.8, H-5), 3.89 (m, 2H, A/B part of a larger
spin system, H-2), 4.09 (m, 2H, A/B part of a larger spin system,
H-3), 4.27 (t, 1H, J5b, 5a/6 = 10.4, H-5b), 5.69 (dd, 1H, J6, 5b
= 10.4, J6, 5a = 8.8, H-6), 7.50 (m, 5H, H-Ar).
13C NMR
(100 MHz, 298.2 K, CD3OD): d= 12.7 (C-299), 38.0 (C-3), 43.5
(C-199), 49.9 (C-2), 56.2 (C-5), 72.3 (C-6), 129.2, 130.8 (4C, C-29,
C-39, C-59, C-69), 131.3 (C-49), 137.1 (C-19), 178.5 (C-8). MS (m/
z): [M]+ calcd, 233.1; found, 233.3. HRMS (m/z): [M]+ calcd for
C13H17N2S, 233.1107; found, 233.1107 (DM, 0.2 ppm).
Table 1. Results of in vitro angiogenesis inhibition of
levamisole and its derivatives in comparison with suramin (5),
vehicle (DMSO), and medium alone, as observed by HUVEC
number and morphology.
Compound Concentration
Area
%a Morphologyb Gradingc
1 (levamisole) 1 mM 7.5 Clusters ++
2 (tetramisole) 1 mM 8.0 Clusters ++
3 1 mM 3.4 Clusters ++++
4 1 mM 2.0 Cords +++
7a 1 mM 2.8 Clusters ++++
7b 1 mM 3.3 Clusters ++++
8a 0.7 mM 5.2 Mixed +
8b 0.2 mM 5.4 Mixed +
9 0.6 mM 2.6 Mixed +
10 0.3 mM 5.0 Mixed +
11a 0.7 mM 2.8 Mixed +
11b 0.4 mM 4.0 Mixed +
12 0.1 mM 3.7 Mixed +
5 (suramin)
Anti-VEGF
1 mM
5 mg/mL
2.2
8.5
Cords
Clusters
+++++
Medium 10.2 Network
DMSO Diluted 1:1000 8.4 Network
aPercent of the area covered by HUVEC as observed by CD31 staining.
bClusters refer to morphologies where several cells that form round or
elongated clusters; Cords refer to morphologies where single to a few cells form
cord-like structures without forming a network.
c(++++) = clusters with area ,4%; (+++) = cords with area ,4%; (++) =
clusters with area .4%; (+) = intermediate morphologies and varying area
percentages.
doi:10.1371/journal.pone.0045405.t001
Table 2. Inhibition of human placenta alkaline phosphatase (HPAP), bovine kidney tissue non-specific alkaline phosphatase
(TNAP) and sirtuin 1 (SIRT1) by selected compounds.
Compound 1 2 3 5 7a 7b 8a 9 11a 11b 12
HPAP IC50 (mM) 1.1 1.2 0.7 ND .2 .2 .2 .2 .2 .2 .2
TNAP IC50 (mM) 0.6 1.0 .2 .2 0.1 .2 .2 .2 .2 .2 .2
SIRT1 inhib. (1 mM)a ND ND ND .90% Not activeb ND ND ND ND ND ND
aSirtuin 1 inhibition was tested for N-methyllevamisole (7a) and suramin (5) as a positive control. b No inhibition was observed at ligand concentrations up to 10 mM. All
assays were performed at least twice in duplicate. ND = not determined.
doi:10.1371/journal.pone.0045405.t002
Figure 7. Test for activation of sirtuin 1 (SIRT1). The ability of
compound 7a to activate SIRT1 mediated deacetylation was tested in
a commercially available fluorogenic assay. Resveratrol was used
a positive control, although its relevance as a direct activator of sirtuin
activity has been called into question recently [59–62]. The data
represent two individual assays performed in duplicate.
doi:10.1371/journal.pone.0045405.g007
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(S)-N-Isopropyllevamisole trifluoroacetate (9)
Levamisole (0.224 g, 1.37 mmol) and 2-iodopropane
(0.137 mL, 1.37 mmol) were subjected to general procedure I,
with stirring under reflux for 3 days. Purification by reversed
phase HPLC provided the title compound as a colorless syrup
(53 mg, 13%). Optical rotation: [a]D –70u (c 0.01, 298.2 K,
CH2Cl2).
1H NMR (400 MHz, 298.2 K, CD3OD): d= 1.11 (d,
3H, J299A/B, 199 = 6.8, H-299AB), 1.28 (d, 3H, J299AB, 199 = 6.8, H-
299AB), 3.63 (h, 1H, J199, 299A/B = 6.8, H-199), 3.75 (dd, 1H, J5a, 5b
= 10.4, J5a, 6 = 8.3, H-5a), 3.86 (m, 2H, A/B part of a larger spin
system, H-2), 4.07 (m, 2H, A/B part of a larger spin system, H-3),
4.24 (t, 1H, J5b, 5a/6 = 10.4, H-5b), 5.70 (dd, 1H, J6, 5b = 10.4, J6,
5a = 8.3, H-6), 7.50 (m, 5H, H-Ar).
13C NMR (100 MHz,
298.2 K, CD3OD): d= 20.3 (C-299A/B), 20.9 (C-299A/B), 38.0 (C-
3), 49.2 (C-2), 52.8 (C-199), 56.3 (C-5), 72.3 (C-6), 129.1 and 130.6
(4C, C-29, C-39, C-59, C-69), 131.1 (C-49), 138.5 (C-19), 177.2 (C-
8). MS (m/z): [M]+ calcd, 247.1; found, 247.3. HRMS (m/z): [M]+
calcd for C14H19N2S, 247.1263; found, 247.1263 (DM, 0.1 ppm).
(S)-N-(n-Butyl)-levamisole trifluoroacetate (10)
Levamisole (0.252 g, 1.24 mmol) and 1-iodobutane (0.176 mL,
1.54 mmol) were reacted according to general procedure I to give
the title compound as a colorless syrup (40 mg, 9%) after reversed
phase HPLC purification. Optical rotation: [a]D –59u (c 0.01,
298.2 K, CH2Cl2).
1H NMR (400 MHz, 298.2 K, CD3OD):
d= 0.86 (t, 3H, J499, 399 = 7.2, H-499), 1.28 (m, 2H, H-399), 1.47 (m,
2H, H-299), 3.14 (dt, 1H, J1a’’, 199b = 14.5, J1a’’, 299 = 6.7, H-199a),
3.27 (dt, 1H, J199b, 1a’’ = 14.5, J199b, 299 = 6.7, H-199b), 3.78 (dd,
1H, J5a, 5b = 10.5, J5a, 6 = 8.9, H-5a), 3.90 (m, 2H, A/B part of
a larger spin system, H-2), 4.09 (m, 2H, A/B part of a larger spin
system, H-3), 4.28 (t, 1H, J5b, 5a/6 = 10.5, H-5b), 5.66 (dd, 1H, J6,
5b = 10.5, J6, 5a = 8.8, H-6), 7.50 (m, 5H, H-Ar).
13C NMR
(100 MHz, 298.2 K, CD3OD): d= 13.9 (C-499), 20.8 (C-399), 30.2
(C-299), 38.0 (C-3), 48.4 and 50.0 (2C, C-2, C-199), 56.1 (C-5), 72.7
(C-6), 129.3, 130.8 (4C, C-29, C-39, C-59, C-69), 131.3 (C-49),
137.0 (C-19), 178.9 (C-8). MS (m/z): [M]+ calcd, 261.1; found,
261.3. HRMS (m/z): [M]+ calcd for C15H21N2S, 261.1419; found,
261.1420 (DM, 0.1 ppm).
(S)-N-Benzyllevamisole (11)
Levamisole (0.290 g, 1.42 mmol) was dissolved in THF (5 mL)
and benzylbromide (0.210 mL, 1.78 mmol) were subjected to
general procedure I, which furnished the bromide (11a) after
lyophilization. A sample (48 mg, 0.14 mmol) of the colorless syrup
was taken up in MeOH (1 mL) and purified by reversed phase
HPLC to give the N-benzyllevamisole trifluoroacetate (11b;
10 mg). Optical rotation (11b): [a]D –46u (c 0.01, 298.2 K,
CH2Cl2).
1H NMR (400 MHz, 298.2 K, CD3OD): d= 3.80 (dd,
1H, J5a, 5b = 10.5, J5a, 6 = 9.3, H-5a), 3.90 (m, 2H, A/B part of
a larger spin system, H-2), 4.04 (m, 2H, A/B part of a larger spin
system, H-3), 4.23 (d, 1H, J199b, 199a = 15.1, H-199b), 4.27 (t, 1H,
J5b, 5a/6 = 10.5, H-5 b), 4.46 (d, 1H, J 199a, 199b = 15.1, H-199a),
5.52 (dd, 1H, J6, 5b = 10.5, J6, 5a = 9.3, H-6), 7.16 (m, 2H, H-399,
H-799), 7.35 (m, 3H, H-499, H-599, H-699), 7.48 (m, 5H, H-Ar). 13C
NMR (100 MHz, 298.2 K, CD3OD): 38.0 (C-3), 50.0 (C-2), 52.0
(C-199), 55.9 (C-5), 72.9 (C-6), 129.4, 130.2, and 130.7 (8C, C-29,
C-39, C-59, C-69, C-399, C-499, C-699, C-799), 130.3 (2C, C-49, C-
599), 133.5 (C-299), 136.5 (C-19), 178.7 (C-8). MS (m/z): [M]+ calcd,
295.1; found, 295.4.
(S)-N-Cyclohexylmethylenelevamisole (12)
Levamisole (6) (0.149 g, 0.73 mmol) and cyclohexyl-bromo-
methane (0.126 mL, 0.91 mmol) were reacted according to
general procedure I, purified by reversed phase HPLC, and
lyophilized to give 12 as the trifluoroacetate (128 mg, 22%).
Optical rotation: [a]D –46u (c 0.01, 298.2 K, CH2Cl2).
1H NMR
(400 MHz, 298.2 K, CD3OD): d= 0.86 (m, 2H, H-599), 1.16 (m,
2H, H-499), 1.15 (m, 1H, H-399B), 1.46 (m, 1H, H-299), 1.54 (m,
1H, H-799A), 1.55 (m, 1H, H-399A), 1.67 (m, 1H, H-799B), 1.69 (m,
2H, H-699), 2.96 (dd, 1H, J199a, 199b = 14.4, J 199a, 299 = 6.29, H-
199a), 3.07 (dd, 1H, J199b, 199a = 14.4, J199b, 299 = 8.44, H-199b), 3.80
(dd, 1H, J5a, 5b = 10.4, J5a, 6 = 8.8, H-5a), 3.87 (m, 1H, A/B part
of a larger spin system, H-2A/B), 3.93 (m, 1H, A/B part of a larger
spin system, H-2A/B), 4.08 (m, 1H, A/B part of a larger spin
system, H-3A/B), 4.10 (m, 1H, AB part of a larger spin system, H-
3A/B), 4.29 (t, 1H, J5b, 5a/6 = 10.4, H-5b), 5.66 (dd, 1H, J6, 5b
= 10.4, J6, 5a = 8.8, H-6), 7.48 (m, 1 H, H-49), 7.49 (m, 2 H, H-39
), 7.51 (m, 2 H, H-29). 13C NMR (100 MHz, 298.2 K, CD3OD):
d= 26.5 (C-699), 26.6 (C-399), 27.1 (C-499), 31.5 (C-799), 31.6 (C-
599), 37.1 (C-299), 37.8 (C-3), 49.9 (C-2), 54.9 (C-199), 55.9 (C-5),
73.0 (C-6), 129.2 (2C, C-29, C-69), 130.7 (2C, C-39, C-59), 131.3
(C-49), 136.9 (C-19), 179.1 (C-8). MS (m/z): [M]+ calcd, 301.1;
found, 301.4. HRMS (m/z): [M]+ calcd for C18H25N2S, 301.1733;
found, 301.1733 (DM, 0.1 ppm).
Endothelial cell culture
Co-culture cell assays were performed according to a method
described previously [38,44]. Briefly, 103 NHDFs were cultured in
each well of a 96-well microtiter plate in NHDF standard medium
(100 mL, FGM-2 Bullet kit) at 37uC in an atmosphere containing
5% CO2. After 3 days the medium was removed and 10
3
HUVECs were seeded onto the NHDF in TFSM2 medium
(135 mL). The samples of the individual compounds were prepared
by weight and dissolved in a concentration of 1 M in DMSO,
PBS, or Milli-Q water followed by pH adjustment, and sterile
filtration through 0.22 mm filters. Medium, buffer controls or test
samples of 15 mL were added to each well containing the
HUVEC–NHDF co-culture and were incubated for 3 days.
Experiments were repeated 2–4 times with identical results.
CD31 immunostaining
HUVEC and fibroblasts were stained with a CD31 antibody
according to the method previously described [38,44]. Briefly, the
cells were washed with PBS, fixed with ethanol, blocked with TTN
buffer, incubated with mouse anti-human CD31 diluted 1:250 in
TTN buffer, washed in TTN buffer and incubated with alkaline
phosphatase-conjugated goat anti-mouse IgG diluted 1:1000 in
TTN buffer. Bound antibody was subsequently visualised with
BCIP/NBT and inspected in an Olympus IX70 microscope and
photographed with an Olympus DP12 digital camera (Magnifica-
tion: 40x). Image analysis was carried out using the program
AnalySIS (Soft Imaging Systems, Mu¨nster, Germany).
Alkaline phosphatase assay
The levamisole derivatives were diluted to 2.5, 5 and 10 mM in
DMSO. Samples (10 mL) and 90 mL solution of alkaline
phosphatase (0.01 U/mL) from human placenta or bovine kidneys
diluted in substrate buffer were added to a 96-well microtiter plate
and incubated for 35 minutes at room temperature. Hereafter,
100 mL p-nitrophenyl phosphate (2 mg/mL) were added, and the
plate was read at 405 nm with background subtraction at 650 nm
on a Versamax Elisa reader (Molecular Devices, Sunnyvale, CA,
USA) after 24 and 35 min. Results were obtained as the mean of
double determinations. The EC50 values were read from the curve
at half maximal absorbance.
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SIRT1 inhibition assay
The assay was performed according to protocols provided by
the supplier (Biomol, BML-AK555). Briefly, the dose–response
experiments were performed in black low binding NUNC 96-well
microtiter plates. The dilution series were prepared in Milli-Q
water from 100 mM DMSO stock solutions. Fluor-de-Lys SIRT1
substrate (250 mM), NAD+ (500 M), and SIRT1 (2 U/well) were
incubated in SIRT assay buffer prepared as described in the
Biomol product sheets [Tris/Cl (50 mM), NaCl (137 mM), KCl
(2.7 mM), MgCl2 (1 mM), pH 8.0, 1 mg/mL bovine serum
albumin] in the presence or absence of the appropriate dilution
of compound 7a or suramin. After 1 hour at 37uC, nicotinamide
(2 mM) and developer (50 mL, 26) were added, and the assay
development was allowed to proceed for 15–30 minutes at room
temperature, before the plate was read using a Tecan plate reader
with excitation at 360 nm and emission at 460 nm. Two
individual assays were performed in duplicate.
SIRT1 activation assay
The assay was essentially performed as described above for the
deacetylase inhibition, but with different concentrations of enzyme
and substrate [Fluor-de-Lys SIRT1 substrate (25 mM), NAD+
(25 mM), SIRT1 (1 U/well)], and using resveratrol as positive
control. Two individual assays were performed in duplicate.
Supporting Information
Table S1 Full assignment of the NMR spectral data
obtained for compound 12.
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